Zimmer Biomet (NYSE:ZBH) Given “Market Outperform” Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of Zimmer Biomet (NYSE:ZBH) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $140.00 price objective on the medical equipment provider’s stock.

A number of other equities analysts have also recently commented on the stock. Barclays cut their target price on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Wells Fargo & Company upped their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday. Oppenheimer decreased their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Finally, Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $124.70.

Zimmer Biomet Price Performance

Shares of ZBH opened at $101.01 on Friday. The firm has a fifty day moving average price of $107.56 and a 200 day moving average price of $108.16. The stock has a market cap of $20.11 billion, a PE ratio of 22.70, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet has a 1-year low of $99.93 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm posted $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently added to or reduced their stakes in ZBH. Equity Investment Corp purchased a new stake in shares of Zimmer Biomet in the third quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after buying an additional 577,320 shares in the last quarter. Van ECK Associates Corp grew its holdings in Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after buying an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in Zimmer Biomet during the third quarter worth $41,588,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at $21,234,000. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.